AZT

AZT
Fvasconcellos · Public domain · source
Name	Zidovudine
Other names	AZT; ZDV; azidothymidine
Class	Nucleoside analogue reverse transcriptase inhibitor
Tradename	Retrovir
Routes of administration	Oral; Intravenous
Legal status	Prescription only
Protein bound	Low
Metabolism	Hepatic (glucuronidation)
Elimination half-life	0.5–3 hours
Excretion	Renal

AZT

AZT is an antiretroviral medication first approved for human use in the 1980s. It belongs to the class of nucleoside analogue reverse transcriptase inhibitors and was the first agent shown to improve survival in patients infected with human immunodeficiency virus. Clinical adoption of the drug influenced research at institutions such as National Institutes of Health, Centers for Disease Control and Prevention, and pharmaceutical companies including Burroughs Wellcome.

Medical uses

AZT is indicated for treatment and prevention of infection by human immunodeficiency virus in adults and neonates. In combination with agents developed by companies like Gilead Sciences and GlaxoSmithKline, regimens including AZT reduce viral replication and are used in antiretroviral therapy protocols endorsed by organizations such as World Health Organization and Joint United Nations Programme on HIV/AIDS. AZT is employed in prevention of vertical transmission during childbirth following guidelines from American College of Obstetricians and Gynecologists and studies conducted at hospitals such as Johns Hopkins Hospital and Massachusetts General Hospital. In occupational exposure, guidance from Occupational Safety and Health Administration and Centers for Disease Control and Prevention has included AZT-containing post-exposure prophylaxis regimens.

Mechanism of action

AZT acts as an analogue of the nucleoside thymidine and targets the reverse transcriptase enzyme of retroviruses. The triphosphate form is incorporated by viral reverse transcriptase, studied in structural analyses at laboratories including Cold Spring Harbor Laboratory and Salk Institute, leading to premature termination of DNA synthesis. Resistance mutations mapped in clinical isolates were characterized by collaborations between University of California, San Francisco and Fred Hutchinson Cancer Research Center, revealing amino acid substitutions in reverse transcriptase that reduce incorporation of the analogue. Biochemical assays developed at institutions such as Rockefeller University and Harvard Medical School clarified competitive inhibition kinetics and the role of host kinases in phosphorylation.

Pharmacology

Pharmacokinetic and pharmacodynamic properties were established in multicenter trials coordinated by groups including National Cancer Institute and European Medicines Agency investigators. After oral administration, AZT is absorbed and undergoes hepatic glucuronidation mediated by enzymes studied at Stanford University School of Medicine; renal excretion is significant, prompting dose adjustment recommendations by panels convened by Food and Drug Administration. The intracellular half-life of the active triphosphate supports multiple-daily dosing strategies devised in clinical trials at University College London and Imperial College London. Drug–drug interaction profiles with agents developed by Roche and Bristol-Myers Squibb were characterized in pharmacology units at University of California, San Diego and Karolinska Institutet.

History and development

Discovery and early development involved scientists at research centers like Brookhaven National Laboratory and pharmaceutical firm Burroughs Wellcome. Initial synthesis traces back to chemists working in contexts related to nucleoside chemistry taught at Oxford University and Cambridge University. Rapid clinical testing occurred amid the AIDS epidemic that mobilized communities represented by ACT UP and clinicians at urban centers such as Mount Sinai Hospital and Bellevue Hospital. Regulatory approval by the Food and Drug Administration followed high-profile advisory committee deliberations that included participation from researchers at Columbia University and advocacy groups influencing policy discussions at United States Congress. International trials coordinated through World Health Organization helped define dosing for diverse populations studied at institutions including University of São Paulo and University of Cape Town.

Adverse effects and toxicity

Hematologic toxicity, including anemia and neutropenia, was documented in trials reported by investigators at Mayo Clinic and Cleveland Clinic. Mitochondrial toxicity—manifesting as myopathy and lactic acidosis—was characterized in case series from centers such as University of Toronto and University of Sydney. Drug safety monitoring by regulatory bodies like the European Medicines Agency and Food and Drug Administration informed warnings and labeling changes following pharmacovigilance reports from hospitals including Bellevue Hospital and Royal Free Hospital. Risk mitigation strategies were developed in clinical guidelines from societies such as Infectious Diseases Society of America and British HIV Association, and research into long-term effects involved cohorts followed at Kaiser Permanente and National Institutes of Health clinical centers.

Regulatory and societal impact

Approval of the drug accelerated formation of policy frameworks at agencies including Food and Drug Administration and Health Canada, and influenced intellectual property debates involving World Trade Organization agreements and advocacy from organizations like Médecins Sans Frontières. The drug’s availability catalyzed activism by groups such as ACT UP and reshaped funding priorities at National Institutes of Health and philanthropic organizations like the Gates Foundation. Global rollout strategies coordinated by Joint United Nations Programme on HIV/AIDS and procurement mechanisms involving Pan American Health Organization impacted treatment scale-up in resource-limited settings served by Partners In Health and Clinton Health Access Initiative, shaping subsequent development of combination antiretroviral therapies by pharmaceutical consortia including Merck and Pfizer.

Category:Antiretroviral drugs